RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:POTENTIAL HOME CANCER TREATMENT10 years ago this company caught my interest, imagination and enthusiasm with the introduction of TLD 1433 and its extraordinary promise. Now, with the company's recent NR, my feelings are renewed with the possibilities of Rutherin and its applications.
In the spirit of imagination, just a question to the board. Given the apparent MOA of Rutherin/ Metformin, Could the company run a trial that focuses not on one indication but multiple indications at the same time. For example, a trial consisting of 100 patients in total:
20 patients with GBM cancer
20 patients with lung cancer
20 patients with colon cancer
20 patients with ovarian cancer
20 patients with prostate cancer
it seems to me that the company is moving towards not simply treating and curing a specific type of cancer but treating and curing cancer wherever it is in the human body in whatever form. To attempt a trial in this form would be jaw dropping. To receive positive results from such trial would change everything.
This whole thing is truly remarkable.
John